Jupiter Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Jupiter Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.9M	Buy	+4,535,080	New	+$17.2M	0.09%	242
2023 Q2	–	Sell	-164,360	Closed	-$1M	–	535
2023 Q1	$1M	Buy	164,360 +13,400	+9%	+$92.5K	0.01%	340
2022 Q4	$963K	Buy	150,960 +82,853	+122%	+$647K	0.01%	372
2022 Q3	$652K	Sell	68,107 -9,088	-12%	-$105K	0.01%	419
2022 Q2	$851K	Buy	+77,195	New	+$1.01M	0.01%	449

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Jupiter Asset Management's IOVA Position: Q2 2026 in Review

Jupiter Asset Management opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 4,535,080 shares worth $18.9M. The stake represents 0.09% of the portfolio and ranks #242 among its holdings. This is a return to the name: Jupiter Asset Management previously reported a position in IOVA as recently as Q1 2023.

Jupiter Asset Management first reported a position in IOVA in Q2 2022 and has held it in 5 quarters since. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Jupiter Asset Management held 4,535,080 shares of Iovance Biotherapeutics worth $18.9M as of Q2 2026.
Iovance Biotherapeutics was a new Jupiter Asset Management position in Q2 2026.
Iovance Biotherapeutics made up 0.09% of Jupiter Asset Management's portfolio in Q2 2026, its #242 holding.
Jupiter Asset Management first reported a position in Iovance Biotherapeutics in Q2 2022 and has held it in 5 quarters since.
293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Jupiter Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.